Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282087 · ClinicalTrials.gov registry record · Phase 2
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
A Phase 2 study, sponsored by Sarcoma Alliance for Research through Collaboration.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT00282087: Completed Phase 2 study, sponsored by Sarcoma Alliance for Research through Collaboration.
NCT00282087 is a Phase 2 study that has completed, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 47 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00282087, a Phase 2 study, has completed, sponsored by Sarcoma Alliance for Research through Collaboration.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this trial is to study the benefits of giving chemotherapy to women after they have had surgical resection of their primary disease and have no evidence of disease remaining(known as adjuvant therapy). The major objective of this study is to determine the progression free survival. The goal is to prevent relapse or recurrence of their uterine leiomyosarcoma.
Interventions
- DRUG gemcitabine, docetaxel, doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2006-01 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
What the finished NCT00282087 record still lists
NCT00282087 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 1 intervention - of which gemcitabine, docetaxel, doxorubicin is the first listed.
NCT00282087 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00282087 about?
NCT00282087 is a clinical study titled "Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma". The purpose of this trial is to study the benefits of giving chemotherapy to women after they have had surgical resection of their primary disease and have no evidence of disease remaining(known as adjuvant therapy). The major objective of this study is to determine the progression free survival. Th...
What is the current status of trial NCT00282087?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2006-01. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00282087?
The interventions under investigation include: gemcitabine, docetaxel, doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00282087?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00282087's enrollment target sits among peer trials
47 1283rd of 2000 higher than 715 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia